AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

Claim 1 (Withdrawn – currently amended): A process of making a human-like glycoprotein in a ~~lower eukaryotic~~ yeast host cell ~~engineered to produce glycoproteins having hybrid or complex N-glycans~~ which is diminished or depleted in the activity of an initiating α-1,6-mannosyltransferase and includes at least an α-1,2-mannosidase activity and a GlcNAc transferase I (GnT I) activity comprising the step of introducing into the cell an *N*-acetylglucosaminyltransferase III (GnT III) catalytic activity.

Claim 2 (Withdrawn – currently amended): A process of making a human-like glycoprotein in a ~~lower eukaryotic~~ yeast host cell ~~engineered to produce glycoproteins having hybrid or complex N-glycans~~ which is diminished or depleted in the activity of an initiating α-1,6-mannosyltransferase and includes at least an α-1,2-mannosidase activity and a GlcNAc transferase I (GnT I) activity comprising the step of expressing in the cell an *N*-acetylglucosaminyltransferase III (GnT III) catalytic) activity.

Claim 3 (Withdrawn – currently amended): A process of making a human-like glycoprotein in a ~~lower eukaryotic~~ yeast host cell ~~engineered to produce glycoproteins having hybrid or complex N-glycans~~ which is diminished or depleted in the activity of an initiating α-1,6-mannosyltransferase and includes at least an α-1,2-mannosidase activity and a GlcNAc transferase I (GnT I) activity comprising the step of expressing in the cell one or more enzymatic activities that produce N-glycans comprising $GlcNAc_3Man_3GlcNAc_2$, $GlcNAc_2Man_3GlcNAc_2$ or $GlcNAc_2Man_5GlcNAc_2$ bisected structures.

Claim 4 (Withdrawn – previously presented): The process of claims 1 or 2, wherein the *N*-acetylglucosaminyltransferase III (GnT III) catalytic activity produces a bisected glycan.

Claim 5 (Withdrawn): The process of claims 1 or 2, wherein the glycoprotein comprises a bisected glycan.

Claim 6 (Withdrawn – previously presented): The process of claims 1 or 2, wherein the activity is intracellular.

Claim 7 (Withdrawn): The process of claims 1, 2, or 3, further comprising the step of isolating the glycoprotein from the host cell.

Claim 8 (Withdrawn – currently amended): The process of claims 1, 2, or 3, wherein the host cell is selected from the group consisting of *Pichia pastoris*, *Pichia finlandica*, *Pichia trehalophila*, *Pichia koclamae*, *Pichia membranaefaciens*, *Pichia opuntiae*, *Pichia thermotolerans*, *Pichia salictaria*, *Pichia guercuum*, *Pichia pijperi*, *Pichia stiptis*, *Pichia methanolica*, *Pichia* sp., *Saccharomyces cerevisiae*, *Saccharomyces* sp., *Hansenula polymorpha*, *Kluyveromyces* sp., and *Candida albicans*, ~~*Aspergillus nidulans*, *Aspergillus niger*, *Aspergillus oryzae*, *Trichoderma reesei*, *Chrysosporium lucknowense*, *Fusarium* sp., *Fusarium gramineum*, *Fusarium venenatum*, and *Neurospora crassa*~~.

Claim 9 (Withdrawn): The process of claim 8, wherein the host cell is selected from the group consisting of *Pichia pastoris*, *Pichia finlandica*, *Pichia trehalophila*, *Pichia koclamae*, *Pichia membranaefaciens*, *Pichia opuntiae*, *Pichia thermotolerans*, *Pichia salictaria*, *Pichia guercuum*, *Pichia pijperi*, *Pichia stiptis*, *Pichia methanolica*, and *Pichia* sp..

Claim 10 (Withdrawn): The process of claim 9, wherein the host cell is *Pichia pastoris*.

Claim 11 (Withdrawn): The process of claims 1, 2, or 3, wherein the glycoprotein is a therapeutic protein.

Claim 12 (Withdrawn): The process of claim 11, wherein the therapeutic protein is selected from the group consisting of erythropoietin, cytokines, coagulation factors, soluble IgE receptor α-chain, IgG, IgG fragments, IgM, interleukins, urokinase, chymase, urea trypsin inhibitor, IGF-binding protein, epidermal growth factor, growth hormone-releasing factor, annexin V fusion protein, angiostatin, vascular endothelial growth factor-2, myeloid progenitor inhibitory factor-1, osteoprotegerin, α-1-antitrypsin, α-feto protein, and DNase II.

Claims 13-75 (Cancelled)

Claim 76 (Currently amended): A yeast host cell ~~engineered to produce glycoproteins having hybrid or complex N-glycans~~ which is diminished or depleted in the activity of an initiating α-1,6-mannosyltransferase and includes at least an α-1,2-mannosidase activity and a GlcNAc transferase I (GnT I) activity comprising an *N*-acetylglucosaminyltransferase III (GnT III) catalytic activity.

Claim 77 (Previously presented): The host cell of claim 76, wherein the catalytic activity is intracellular.

Claim 78 (Previously presented): The host cell of claim 76, wherein the cell produces *N*-glycans comprising $GlcNAcMan_3GlcNAc_2$ structures that are capable of reacting with the GnT III catalytic activity.

Claim 79 (Previously presented): The host cell of claim 76, wherein the *N*-acetylglucosaminyltransferase III (GnT III) catalytic activity produces a bisected glycan.

Claim 80 (Previously presented): The host cell of claim 76, wherein the host cell is selected from the group consisting of *Pichia pastoris*, *Pichia finlandica*, *Pichia trehalophila*, *Pichia koclamae*, *Pichia membranaefaciens*, Pichia opuntiae, *Pichia thermotolerans*, *Pichia salictaria*, *Pichia guercuum*, *Pichia pijperi*, *Pichia stiptis*, *Pichia methanolica*, *Pichia* sp., *Saccharomyces cerevisiae*, *Saccharomyces* sp., *Hansenula polymorpha*, *Kluyveromyces* sp., and *Candida albicans*.

Claim 81 (Currently amended): A yeast host cell ~~engineered to produce glycoproteins having hybrid or complex N-glycans~~ which is diminished or depleted in the activity of an initiating α-1,6-mannosyltransferase and includes at least an α-1,2-mannosidase activity and a GlcNAc transferase I (GnT I) activity comprising an *N*-acetylglucosaminyltransferase II (GnT II) catalytic activity and an *N*-acetylglucosaminyltransferase III (GnT III) catalytic activity.

Claim 82 (Previously presented): The host cell of claim 81, wherein the catalytic activity is intracellular.

Claim 83 (Previously presented): The host cell of claim 81, wherein the cell produces *N*-glycans comprising GlcNAcMan3GlcNAc2 structures that are capable of reacting with the GnT III catalytic activity.

Claim 84 (Previously presented): The host cell of claim 81, wherein the *N*-acetylglucosaminyltransferase III (GnT III) catalytic activity produces a bisected glycan.

Claim 85 (Previously presented): The host cell of claim 81, wherein the host cell is selected from the group consisting of *Pichia pastoris*, *Pichia finlandica*, *Pichia trehalophila*, *Pichia koclamae*, *Pichia membranaefaciens*, Pichia opuntiae, *Pichia thermotolerans*, *Pichia salictaria*, *Pichia guercuum*, *Pichia pijperi*, *Pichia stiptis*, *Pichia methanolica*, *Pichia* sp., *Saccharomyces cerevisiae*, *Saccharomyces* sp., *Hansenula polymorpha*, *Kluyveromyces* sp., and *Candida albicans*.

Claim 86 (Currently amended): A yeast host cell ~~engineered to produce glycoproteins having hybrid or complex N-glycans~~ which is diminished or depleted in the activity of an initiating α-1,6-mannosyltransferase and includes at least an α-1,2-mannosidase activity and a GlcNAc transferase I (GnT I) activity comprising an *N*-acetylglucosaminyltransferase III (GnT III) catalytic activity and a mannosidase II catalytic activity.

Claim 87 (Previously presented) The host cell of claim 86, further comprising an *N*-acetylglucosaminyltransferase II catalytic activity.

Claim 88 (Previously presented) The host cell of claim 76 that is deficient in an *OCH1* mannosyltransferase activity.

Claim 89 (Previously presented) The host cell of claim 81 that is deficient in an *OCH1* mannosyltransferase activity.

Claim 90 (Previously presented) The host cell of claim 86 that is deficient in an *OCH1* mannosyltransferase activity.

Claim 91 (Previously presented) The host cell of claim 76 that is deficient in the Dol-P-Man:Man5GlcNAc2-PP-Dol mannosyltransferase activity.

Claim 92 (Previously presented) The host cell of claim 81 that is deficient in the Dol-P-Man:$Man_5GlcNAc_2$-PP-Dol mannosyltransferase activity.

Claim 93 (Previously presented) The host cell of claim 86 that is deficient in the Dol-P-Man:$Man_5GlcNAc_2$-PP-Dol mannosyltransferase activity.

Claim 94 (Previously presented) The host cell of claim 76, further comprising a UDP-GlcNAc transporter.

Claim 95 (Previously presented) The host cell of claim 81, further comprising a UDP-GlcNAc transporter.

Claim 96 (Previously presented) The host cell of claim 86, further comprising a UDP-GlcNAc transporter.